Invasive lobular carcinoma (ILC) is the second most common form of breast cancer. ILC presents at later stages with many challenges, therefore improved diagnostic and therapeutic targets are needed. A microRNA (miRNA) genome analysis identified miR-23c and miR-23b-3p as possible regulators of ILC invasion due to their significantly increased expression in invasive compared to minimally invasive ILC cell lines. By decreasing the levels of miR-23c and miR-23b-3p using hairpin inhibitors, the invasive MDA-MB-330 cell line had significantly reduced invasion, while overexpressing these miRNAs using mimics in the minimally invasive MDA-MB-134VI cell line increased invasion. During the course of this study, it became apparent that limited tools exist for studying invasive ILC. Therefore, two more invasive ILC cell line models were created by isolating and expanding MDA-MB-134VI cells that had invaded through Matrigel® coated invasion chambers. This thesis has thus created new models of invasive ILC as well as identified miR-23c and miR-23b-3p as regulators of MDA-MB-330 and MDA-MB-134VI cell line invasion.

Background. For years, the treatment for invasive lobular carcinoma (ILC) has been mastectomy secondary to the lack of studies investigating the efficacy of breast conservation therapy on patients afflicted with ILC and due to the lack of long-term follow up investigating locoregional recurrence in this patient population. In this article we report the clinical course of a patient diagnosed with ILC. Case report. We describe the case of a 50-year-old woman with stage IIB (T2N1M0) ER/PR positive right breast ILC who underwent a right modified radical mastectomy, postoperative chemotherapy, a prophylactic left simple mastectomy with bilateral breast reconstruction and tamoxifen. Approximately 12 years later, she presented with a deflated breast implant and recurrent breast cancer with metastatic spread. She received palliative radiotherapy then palliative chemotherapy. Unfortunately, she succumbed to the cancer less than a year after being diagnosed with metastatic disease. Conclusions. This may be the first case report of a ruptured breast implant presenting at the same time as the diagnosis of recurrent breast cancer.